Brian Rodrigues

Dr. Brian Rodrigues


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
DADing An
Ding An
BRBrian Rodrigues
Brian Rodrigues
In patients with diabetes, an increased risk of symptomatic heart failure usually develops in the presence of hypertension or ischemic heart disease. However, a predisposition to heart failure might also reflect the effects of underlying abnormalities in diastolic function that can occur in asymptomatic patients with diabetes alone (termed diabetic cardiomyopathy). Evidence of cardiomyopathy has also been demonstrated in animal models of both Type 1 (streptozotocin-induced diabetes) and Type 2 diabetes (Zucker diabetic fatty rats and ob/ob or db/db mice). During insulin resistance or diabetes, the heart rapidly modifies its energy metabolism, resulting in augmented fatty acid and decreased glucose consumption. Accumulating evidence suggests that this alteration of cardiac metabolism plays an important role in the development of cardiomyopathy. Hence, a better understanding of this dysregulation in cardiac substrate utilization during insulin resistance and diabetes could provide information as to potential targets for the treatment of cardiomyopathy. This review is focused on evaluating the acute and chronic regulation and dysregulation of cardiac metabolism in normal and insulin-resistant/diabetic hearts and how these changes could contribute toward the development of cardiomyopathy.

18 February 2007 in Nature Medicine
Verified
Journal Article
Closed access
LBLiam R Brunham
Liam R Brunham
JKJanine K Kruit
Janine K Kruit
TPTerry D Pape
Terry D Pape
JTJenelle M Timmins
Jenelle M Timmins
ARAnne Q Reuwer
Anne Q Reuwer
MHMichael R. Hayden
Michael R. Hayden

1 March 1998 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
BRBrian Rodrigues
Brian Rodrigues
MCMargaret C. Cam
Margaret C. Cam
JMJohn H. McNeill
John H. McNeill

1 October 1992 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
BRBrian Rodrigues
Brian Rodrigues
JMJohn H McNeill
John H McNeill
Brian Rodrigues, John H McNeill; The diabetic heart: metabolic causes for the development of a cardiomyopathy, Cardiovascular Research, Volume 26, Issue 10, 1

1 January 1995 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
BRBrian Rodrigues
Brian Rodrigues
MCM Cam
M Cam
JMJ Mcneill
J Mcneill

21 December 2012 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
PPPrasanth Puthanveetil
Prasanth Puthanveetil
AWAndrea Wan
Andrea Wan
BRBrian Rodrigues
Brian Rodrigues
Diabetic cardiomyopathy is a term used to describe cardiac muscle damage-induced heart failure. Multiple structural and biochemical reasons have been suggested to induce this disorder. The most prominent feature of the diabetic myocardium is attenuated insulin signalling that reduces survival kinases (Akt), potentially switching on protein targets like FoxOs, initiators of cell death. FoxO1, a prominent member of the forkhead box family and subfamily O of transcription factors and produced from the FKHR gene, is involved in regulating metabolism, cell proliferation, oxidative stress response, immune homeostasis, pluripotency in embryonic stem cells, and cell death. In this review we describe distinctive functions of FoxOs, specifically FoxO1 under conditions of nutrient excess, insulin resistance and diabetes, and its manipulation to restore metabolic equilibrium to limit cardiac damage due to cell death. Because FoxO1 helps cardiac tissue to combat a variety of stress stimuli, it could be a major determinant in regulating diabetic cardiomyopathy. In this regard, we highlight studies from our group and others who illustrate how cardiac tissue-specific FoxO1 deletion protects the heart against cardiomyopathy and how its down-regulation in endothelial tissue could prevent against atherosclerotic plaques. In addition, we also describe studies that show FoxO1's beneficial qualities by highlighting their role in inducing anti-oxidant, autophagic, and anti-apoptotic genes under stress conditions of ischaemia–reperfusion and myocardial infarction. Thus, the aforementioned FoxO1 traits could be useful in curbing cardiac tissue-specific impairment of function following diabetes.